- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
- Paralegals
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 25, 2023Jake Holdreith Admitted to American College of Trial Lawyers
-
September 22, 2023Robins Kaplan Attorneys Named 2023 New York Super Lawyers and Rising Stars
-
September 12, 2023Annie Huang Receives Asian Leadership Award from Profiles in Diversity Journal
-
September 26-28, 20236th Annual LF Dealmakers Forum
-
September 28-29, 20232023 Midwest IP Institute
-
October 4, 2023Lying, Cheating, and Stealing Seminar 2023
-
September 2023Evenstad Family Trial Aftermath: Rule 408 May Not Be Used as a Sword and Shield
-
September 2023Meet Our Keynote Speaker: Journalist and New York Times Contributor Katie Engelhart
-
September 2023Walking the Razor’s Edge: Client Capacity and the Attorney-Client Relationship
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generically Speaking: A Hatch-Waxman Litigation Bulletin
By Oren Langer, Christopher Pinahs, and Bernard Pound
Second Quarter
The Summer 2022 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue we review Q2 cases and issue(s) presented:
- Novartis Pharms. Corp. v. Accord Healthcare, Inc.
Gilenya® (fingolimod HCl)
The Federal Circuit granted Defendants’ petition for panel rehearing, vacated its prior decision, and reversed the district court’s judgment that the asserted claims were not invalid for inadequate written description. - Bausch Health Ireland, Ltd. v. Padagis Israel Pharms., Ltd.
Duobrii® (halobetasol propionate / tazarotene)
The court granted summary judgment of no inequitable conduct. - Astellas US LLC v. Hospira, Inc.
Lexiscan® (regadenoson)
After bench trial, the Court found that the patents-in-suit were not infringed by Hospira.
Relevant ANDA updates highlighted in this issue:
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Oren Langer, Christopher Pinahs, Emily Tremblay, and Bernard Pound
Related Professionals
Generically Speaking: A Hatch-Waxman Litigation Bulletin
Read Full Bulletin Related Publications
Second Quarter
Generically Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
Second Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
Second Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
Second Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
Second Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.